The DOI matches its Crossref record; 89 of the 89 references it cites were found in a registry or an index.
Gold compounds as therapeutic agents for human diseases
Abstract
The application of gold in medicine is traceable for several thousand years and Au(i) compounds have been used clinically to treat rheumatoid arthritis since the last century. Recently research into gold-based drugs for a range of human diseases has seen a renaissance. Old as well as new Au(i) and Au(iii) compounds have been used and designed with an aim of targeting cellular components that are implicated in the onset or progression of cancers, rheumatoid arthiritis, viral and parasitic diseases. In addition, new disease targets have been found for gold compounds that have given insight into the mechanism of action of these compounds, as well as in the molecular pathophysiology of human diseases. Here we discuss the rationale for the design and use of gold compounds that have specific and selective targets in cells to alleviate the symptoms of a range of human diseases. We summarise the most recent findings in this research and our own discoveries to show that gold compounds can be developed to become versatile and powerful drugs for diseases caused by dysfunction of selenol and thiol containing proteins.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Palella, F. J., Delaney, K. M., Moorman, A. C., Loveless, M. O., Fuhrer, J., Satten, G. A., Aschman, D. J., & Holmberg, S. D. (1998) · New England Journal of Medicine · doi:10.1056/nejm199803263381301 · Cited by 9,405
Physiological functions of thioredoxin and thioredoxin reductase
Arnér, E. S. J., & Holmgren, A. (2000) · European Journal of Biochemistry · doi:10.1046/j.1432-1327.2000.01701.x · Cited by 2,525
Mitochondrial Membrane Potential in Living Cells
Chen, L. B. (1988) · Annual Review of Cell Biology · doi:10.1146/annurev.cb.04.110188.001103 · Cited by 1,037
Shaw, C. F. (1999) · Chemical Reviews · doi:10.1021/cr980431o · Cited by 990
On the medicinal chemistry of gold complexes as anticancer drugs
Ott, I. (2009) · Coordination Chemistry Reviews · doi:10.1016/j.ccr.2009.02.019 · Cited by 825
Focus on mammalian thioredoxin reductases — Important selenoproteins with versatile functions
Arnér, E. S. J. (2009) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/j.bbagen.2009.01.014 · Cited by 673
Hickey, J. L., Ruhayel, R. A., Barnard, P. J., Baker, M. V., Berners-Price, S. J., & Filipovska, A. (2008) · Journal of the American Chemical Society · doi:10.1021/ja804027j · Cited by 599
Self-citationThioredoxin reductase: A target for gold compounds acting as potential anticancer drugs
Bindoli, A., Rigobello, M. P., Scutari, G., Gabbiani, C., Casini, A., & Messori, L. (2009) · Coordination Chemistry Reviews · doi:10.1016/j.ccr.2009.02.026 · Cited by 595
Delocalized lipophilic cations selectively target the mitochondria of carcinoma cells
Modica-Napolitano, J. S., & Aprille, J. R. (2001) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(01)00125-9 · Cited by 576
Human Placenta Thioredoxin Reductase
Gromer, S., Arscott, L. D., Williams, C. H., Schirmer, R. H., & Becker, K. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.32.20096 · Cited by 536
Cited by
Metal N-heterocyclic carbene complexes as potential antitumor metallodrugs
Liu, W., & Gust, R. (2013) · Chem. Soc. Rev. · doi:10.1039/c2cs35314h · Cited by 762
Chemical biology of anticancer gold(iii) and gold(i) complexes
Zou, T., Lum, C. T., Lok, C.-N., Zhang, J.-J., & Che, C.-M. (2015) · Chemical Society Reviews · doi:10.1039/c5cs00132c · Cited by 628
N-Heterocyclic carbene metal complexes in medicinal chemistry
Oehninger, L., Rubbiani, R., & Ott, I. (2013) · Dalton Trans. · doi:10.1039/c2dt32617e · Cited by 560
Hypoxia-targeted drug delivery
Sharma, A., Arambula, J. F., Koo, S., Kumar, R., Singh, H., Sessler, J. L., & Kim, J. S. (2019) · Chemical Society Reviews · doi:10.1039/c8cs00304a · Cited by 542
Binding of transition metal ions to albumin: Sites, affinities and rates
Bal, W., Sokołowska, M., Kurowska, E., & Faller, P. (2013) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/j.bbagen.2013.06.018 · Cited by 489
Bertrand, B., & Casini, A. (2014) · Dalton Trans. · doi:10.1039/c3dt52524d · Cited by 441
Next-Generation Metal Anticancer Complexes: Multitargeting via Redox Modulation
Romero-Canelón, I., & Sadler, P. J. (2013) · Inorganic Chemistry · doi:10.1021/ic400835n · Cited by 396
Smith, B. R., Eastman, C. M., & Njardarson, J. T. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm501105n · Cited by 372
Update on metal N-heterocyclic carbene complexes as potential anti-tumor metallodrugs
Liu, W., & Gust, R. (2016) · Coordination Chemistry Reviews · doi:10.1016/j.ccr.2016.09.004 · Cited by 351
Anticancer cyclometalated complexes of platinum group metals and gold
Cutillas, N., Yellol, G. S., de Haro, C., Vicente, C., Rodríguez, V., & Ruiz, J. (2013) · Coordination Chemistry Reviews · doi:10.1016/j.ccr.2013.03.024 · Cited by 332
Silver coordination compounds: A new horizon in medicine
Medici, S., Peana, M., Crisponi, G., Nurchi, V. M., Lachowicz, J. I., Remelli, M., & Zoroddu, M. A. (2016) · Coordination Chemistry Reviews · doi:10.1016/j.ccr.2016.05.015 · Cited by 324
Thangamani, S., Maland, M., Mohammad, H., Pascuzzi, P. E., Avramova, L., Koehler, C. M., Hazbun, T. R., & Seleem, M. N. (2017) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2017.00004 · Cited by 90
Metadata
- Authors
- Berners-Price, S. J., & Filipovska, A.
- Venue
- Metallomics
- Publisher
- Oxford University Press (OUP)
- Published
- 2011
- Volume
- 3
- Issue
- 9
- Pages
- 863
- ISSN
- 1756-5901 (ISSN-L)
- 1756-591X
- OpenAlex
- W2095157449
- Cited by
- 495
- References
- 89
- FWCI
- 15.30
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.